Right you are! PROVE 1 and 2 didn't enroll cirrhotic patients, and as you've previously posted in #msg-37316151, it is an important and surprising finding. One expects that absorption of a PIs should varied significantly by fibrosis score in patients with advanced fibrosis/cirrhosis. This is important as this subgroup is among the hardest patients to treat.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.